(Q70238754)
Statements
Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects (English)
R M Bukowski
S Murthy
J Sergi
G T Budd
S McKeever
S V Medendorp
R Tubbs
V Gibson